A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines  by Cattaneo, M.G. et al.
FEBS Letters 397 (1996) 164168 FEBS 17765 
A somatostatin analogue inhibits MAP kinase activation and 
cell proliferation in human neuroblastoma and in human small cell 
lung carcinoma cell lines 
M.G. Cattaneo”, D. Amoroso”, G. Gussonib, A.M. Sanguinib, L.M. Vicentini”l* 
‘Department of Pharmacology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy 
hIpsen S.p.A., Milan, Italy 
Received 1 August 1996 
Abstract Somatostatin possesses antlsecretory and antiprolif- 
erative activity on some human tumors. We herein report that, in 
a human neuroblastoma cell line, the somatostatin analogue BIM 
23014 inhibited mitogen-activated protein (MAP) kinase activity 
stimulated by either insulin-like growth factor-l, whose receptor 
bears a tyrosine kinase, or carbachol, which acts at a G-protein 
coupled receptor. In a human small cell lung carcinoma line BIM 
inhibited serum-stimulated MAP kinase activation. These 
inhibitory actions occur in a dose range quite similar to that 
observed for suppression of proliferation induced by the analogue 
in the same cell lines. The decrease in CAMP elicited by the 
analogue in the two cell lines is not responsible for its inhibitory 
action on MAP kinase and cell growth. Moreover, the analogue 
did not modify intracellular [Ca*+] and pH. An involvement of a 
phosphatase activity is suggested. 
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1. Introduction 
Somatostatin (SST) is a peptide hormone which plays an 
important role in controlling the endocrine, paracrine and 
autocrine secretion of several anterior pituitary and gastroin- 
testinal hormones [1,2]. 
SST has been shown also to possess an antiproliferative 
effect in some human cancers including breast cancer, pan- 
creatic cancer, small cell lung carcinoma and neuroblastoma 
[3]. The biological activity of the peptide is dependent on its 
interaction with specific receptors, the structures of which 
have recently been elucidated from cloning experiments [4]. 
Five distinct SST receptor genes have been cloned and the 
corresponding receptors are all members of a G-protein 
coupled, seven transmembrane domain family. Some of these 
receptors (if not all) are coupled to adenylate cyclase in an 
inhibitory fashion [4]. 
Both human small cell lung carcinoma (SCLC) and neuro- 
blastoma (NB) are tumors characterized by a poor prognosis 
and unsuccessful pharmacological treatment. To find a new 
pharmacological approach to control malignant cell prolifera- 
tion would be of great value. The recent availability of a 
potent and long lasting SST analogue (BIM 23014, also 
known as lanreotide [S]) has allowed us to further investigate 
the antiproliferative effect of this SST-like agent in SCLC and 
NB and to attempt to understand its cellular mechanism(s) of 
action. We found that BIM inhibited MAP kinase activity 
stimulated by different types of mitogens in a dose range 
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similar to that necessary for inhibition of cell proliferation. 
A decrease in CAMP or modification of intracellular Ca2+ 
concentration ([Ca’+]i) and pH were not involved in the ana- 
logue’s antimitogenic action. 
2. Materials and methods 
2.1. Cell lines 
Small cell lung carcinoma cell lines (GLC-8, NCI-N-592 and H-69) 
and neuroblastoma cell line (SYSY) were routinely grown in RPMI- 
1640 medium (Sigma Chemicals, St. Louis, MO, USA) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Grand 
Island, NY, USA). All the cell lines were kept at 37°C in a humidified 
atmosphere of 5% CO2 in air. 
2.2. Mitogenicity assay 
SCLC cells were plated in RPMI-1640 medium supplemented with 
10% FBS in 96-well microtiter plates, at a density of lo5 cells/well, 
treated with the indicated concentrations of BIM and incubated for 48 
h. Quiescent SYSY cells, plated at a density of 2 X lo4 cells/well, were 
stimulated with serum or IGF-1, in the presence or in the absence of 
BIM, for 48 h. BIM was added twice a day during the 48 h of 
incubation. [3H]Thymidine (1 @/well; specific activity 2 Ctimmol, 
Amersham, UK) was added during the last 6 h of incubation. 
SCLC cells were then collected on filters with an automatic cell har- 
vester (Titerteck, Flow Laboratories, Rockville, MD, USA) and the 
filters were counted using standard procedures. SYSY cells were ex- 
tracted in 10% TCA and the radioactivity incorporated into TCA 
insoluble material was evaluated after solubilization in NaOH 0.5 M. 
2.3. Determination of MAP kinase activity 
H-69 and SYSY cells were serum-deprived for 48 h in RPM1 alone 
or in 0.1% FBS in RPMI, respectively. The cells (1.5-2.0 X 106) were 
preincubated with BIM or forskolin for 10 min before treatment with 
the various stimuli. After 5 min, the medium was removed and the 
cells were washed and resuspended (H-69 cells) or scraped (SYSY 
cells) in 0.5 ml of homogenization buffer, according to Seger et al. 
[6]. After sonication (2 X 7 s) and centrifugation (15 000 X g for 10 min 
at 4”C), the supernatants were fractionated on DEAE-cellulose mini- 
columns. MAP kinase activity was determined by phosphate incor- 
poration into myelin basic protein (MBP, Sigma) in the presence of 
[y-32P]ATP (2 uCi/sample; specific activity 3000 Ci/mmol; Amersham, 
UK), also according to Seger et al. [6]. 
2.4. Determination of adenylate cyclase activity 
Adenylyl cyclase assays were performed with membrane prepara- 
tions stimulated by forskolin, as previously described [7,8]. 
2.5. Caz+ measurements with fura- 
The cells were washed in Krebs-Ringer-HEPES medium (KRH) 
containing (in mM): 125 NaCl; 5 KCl; 1 KHsP04; 2 MgS04; 0.5 
CaC&; 25 HEPES-NaOH, pH 7.4; 6 glucose and 1 mg/ml bovine 
serum albumin. The cells were then incubated for 30 min, at 37°C 
with the Ca2+-sensitive dye fura- (Calbiochem, San Diego, CA, 
USA), added as the acetoxymethylester, at a final concentration of 
2 FM. After rinsing once with KRH medium, aliquots (5X lo6 cells 
for H-69 and 1.5 X lo6 for SY5Y) of the cell suspension were trans- 
ferred to a thermostated cuvette (34°C) in a volume of 1.5 ml, main- 
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Fig. 1. BIM 23014 inhibition of serum-stimulated DNA synthesis in H-69 cells (A) and of serum- and IGF-l-induced DNA synthesis in SYSY 
cells (B). A: H-69 cells incubated in 10% FBS; B: quiescent SYSY cells incubated in RPM1 containing 10% FBS (0) or IGF-1 100 &ml (0). 
The cells were treated for 10 min with increasing concentrations of BIM 23014 before the addition of mitogens. The experiments were then per- 
formed as described in Section 2. Data are expressed: in (A) as cpm of [3H]thymidine (t3H]Thd) incorporated by the cells; in (B) as differences 
(Acpm) of the [3H]Thd incorporated by the stimulated cells over the [3H]Thd incorporated by control cells (RPM1 alone, 26381+4316 cpm; 
n = 3) and are the mean f S.D. of triplicate samples from a representative experiment which was repeated twice with similar results. 
tained under continuous stirring and analyzed in a Perkin Elmer LS/ 
5B fluorometer. Calibrations for [Ca’+] were carried out as previously 
described [9]. 
3. Results 
Fig. 1A shows that the SST analogue BIM 23014 inhibited 
[3H]thymidine ([3H]Thd) incorporation in H-69 cells in the 
presence of 10% FBS in a concentration-dependent manner. 
Maximum inhibition (about 25%) was obtained at 100 nM. 
The I&,, based upon the maximum reduction in [3H]Thd 
incorporation, was estimated to be approximately 350 pM. 
At the highest concentration tested (1 PM) the analogue lost 
its action and the [3H]Thd incorporation returned to normal 
levels. In similar experiments performed in two other SCLC 
cell lines (GLC-8 and NCI-N-592) BIM, at the same concen- 
trations, was unable to modify DNA synthesis (data not 
shown). 
A substantially greater decrease of [3H]Thd incorporation 
following BIM administration was observed also in the neu- 
roblastoma cell line SYSY (Fig. 1B). The cells were made 
quiescent by serum deprivation for 24 h and then stimulated 
with serum or IGF-1 in the presence or in the absence of 
increasing concentrations of BIM. The maximal inhibition 
against both stimuli was about 50% and the ICsos, calculated 
as described above, were estimated to be approximately 500 
PM. 
Having established the antiproliferative role for the SST 
analogue in the two cell lines, we next examined the possible 
cellular mechanisms that might be responsible for this action. 
Since serum- and IGF-l-stimulated DNA synthesis is meas- 
ured many hours after the application of the analogue, we 
decided to investigate the effect of BIM on a much earlier 
event elicited by mitogens (i.e. MAP kinase activation). Fig. 
2A,B shows that BIM was capable also of completely inhibit- 
ing serum-stimulated MAP kinase activity in the two cell lines 
examined. BIM was administered 10 min before the stimuli, 
which were applied to the cells for an additional 5 min. In 
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Fig. 2. BIM 23014 inhibition of serum-induced MAP kinase activity in H-69 cells (A) and SYSY cells (B). Cells were preincubated for 10 min 
with the indicated concentrations of BIM 23014 and then stimulated with 20% FBS for 5 min. MAP kinase activity was evaluated as described 
in Section 2. Data are expressed as fold of pmol of 32P incorporated by MBP/min/mg protein under basal conditions (i.e. in the presence of ex- 
tracts obtained from untreated cells; these values are 6.53 f0.87 and 1.76+0.17 pmol/min/mg protein for H-69 and SYSY cells, respectively; 
n = 6). Each point is the mean + S.E.M. of three separate experiments, each performed in duplicate. 
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Fig. 3. BIM 23014 inhibition of MAP kinase activity stimulated by 
IGF-1 and carbachol in SYSY cells. SYSY cells were stimulated for 
5 min with 100 ng/ml IGF-1 or 1 mM carbachol (cch) after 10 min 
of preincubation with medium alone (open bars) or 1 nM BIM 
23014 (hatched bars). Data are expressed as pmol of 32P incorpo- 
rated by MBP/min/mg protein and are the mean & S.E.M. of three 
separate experiments, each performed in duplicate. 
H-69 cells, it appears that 1 nM BIM brought MAP kinase 
activity back to basal levels while 1 pM was without addi- 
tional effect upon this enzyme activity. In SYSY cells the ICsa 
for the inhibitory effect on the kinase activity was estimated to 
be 100 pM. As illustrated in Fig. 3, BIM, at a concentration 
of 1 nM, completely inhibited the MAP kinase activation 
induced by both IGF-1, a tyrosine kinase receptor agonist, 
and by carbachol, whose receptors belong to the seven trans- 
membrane G-protein coupled family and are reported to be 
expressed in SYSY cells [lo]. 
We were interested in understanding the intracellular sig- 
nal(s) elicited by BIM which lead to inhibition of MAP kinase 
activity. Five types of SST receptors have recently been cloned 
[4] and at least some (if not all) of them are negatively coupled 
to adenylate cyclase (AC). The inhibition of forskolin-induced 
CAMP formation in H-69 and SYSY cell membranes by BIM 
is shown in Table 1. However, as shown in Fig. 4A,B, intro- 
duction of the CAMP analogue S-bromo-adenosine cyclic 3’- 
5’-monophosphate (8-BrcAMP, 1 mM) inhibited the incor- 
poration of [“H]Thd stimulated by serum (A, H-69 cells) 
and by serum and IGF-1 (B, SYSY cells). Moreover, the ex- 
posure to forskolin completely inhibited the serum-stimulated 
MAP kinase activity in both H-69 and SYSY cell lines (Fig. 
40 
From these results it appears that the inhibition of MAP 
kinase activity and of cell proliferation by BIM are mediated 
by an intracellular signal distinct from CAMP. 
It has been reported that SST inhibits the voltage-depend- 
ent Ca’+ channels (VDCCs) and as a consequence the depol- 
arization-induced [Ca’+]i increase and hormone release from 
pituitary cells [11,12]. Both H-69 and SYSY cells are known 
to possess VDCCs [13,14] and to contain peptides which can 
be released and possibly act as autocrine growth factors 
Table 1 
Adenylate cyclase activity in membranes of H-69 and SYSY cells 
Cell line Basal 
H-69 27.3 + 1.4 
SYSY 35.1 t 2.0 
Forskolin 50 uM Forskolin 50 uM+BIM 23014 1 uM Inhibition (%) 
465.2 + 22.0 292.9? 33.1 37.0 
382.8 f 20.2 301.7 + 5.9 21.0 
[15,16]. Since MAP kinase activity has been shown to be stim- 
ulated by calcium in some types of cells [17], measurements of 
[Ca2+]i were carried out by the fura- technique in both cell 
lines and the effect of BIM tested. H-69 and SYSY cells were 
found to have a resting [Ca2+]i of 35 t 10 and 75 f 11 nM, 
respectively (n = 7). After depolarization with 50 mM KCl, 
[Ca’+]i went to 70? 15 and 148 f 14 nM, respectively (n = 5). 
Pretreatment of the cells with BIM (100 nM) had no effect, 
either on the resting [Ca’+]i (42 & 7 and 60 + 16 nM for H-69 
and SYSY cells respectively; it = 5) nor on the KCl-stimulated 
[Ca2+]i rise (75 + 10 and 135 f 20 nM, n = 5). 
It has been reported that in enteric endocrine cells SST 
causes an acidification of intracellular pH via inhibition of 
Na+/H+ exchange [18]. In both cell lines the administration 
of BIM did not induce any variation in the cytoplasmic pH, 
as measured by the fluorescent probe BCECF (data not 
shown). 
4. Discussion 
We show here that the SST analogue BIM inhibited 
[“H]Thd incorporation in one out of three small cell carcino- 
ma cell lines tested in accordance with the data in the litera- 
ture, where only a percentage of the SCLC express somato- 
statin receptors [19]. By inference, the resistant SCLC lines 
used in our study were likewise devoid of SST receptors, 
although this remains to be establish as the cause of their 
resistant nature. The biphasic concentration-response curve 
most likely derives from a desensitization of the receptors at 
the higher concentrations used (1 PM). The data suggest the 
existence of a precise concentration range to be used to obtain 
the antiproliferative effect in these cells. BIM was also capable 
of inhibiting [3H]Thd incorporation in human neuroblastoma 
cells used (SYSY) to a greater extent than H-69 cells. 
Having established the antiproliferative effect of BIM in the 
two cell lines, we then attempted to elucidate the cellular 
mechanism(s) affected by the analogue which might be re- 
sponsible for its action. First of all, since [3H]Thd incorpora- 
tion is tested many hours after both drug and mitogen expo- 
sure, we measured a much earlier event stimulated by growth 
factors (i.e. the activation of MAP kinase). MAP kinases be- 
long to a family of phosphorylating enzymes which integrate 
and amplify messages from different growth factors and are 
considered crucial for the immediate transmission of the mi- 
togenic signal from the membrane to the nucleus [20]. Our 
finding that BIM inhibited MAP kinase activity suggests 
that its site of action is close to sites responsible for cellular 
events triggered immediately after the growth factor-receptor 
interaction. Since the analogue was capable of inhibiting the 
MAP kinase activity stimulated by both IGF-1, which possess 
a tyrosine kinase receptor, and by carbachol, whose receptor 
is G protein-coupled, its site of action might presumably be 
on some step common to the two pathways leading to MAP 
kinase activation. BIM was able to block the MAP kinase 
The assays were performed as described in Section 2. Results are expressed as pmol cAMP/min/mg protein and are the meanfS.D. of a 
representative experiment that was repeated once with similar results. 
M.G. Cuttanea ef ai.lFEBS Letters 397 (1996) 1644168 
02 
SY5Y cells 
167 
Fig. 4. Elevation of intracellular CAMP inhibited serum- and IGF-l-induced DNA synthesis and MAP kinase activity in H-69 and SY5Y cells, 
A: H-69 cells; B: SYSY cells. Cells were incubated in RPM1 alone (open bars) or containing 10% FBS (hatched bars) or IGF-I 100 @ml (sol- 
id bars). When indicated, 1 mM BrcAMP was added 10 min before mitogens. The experiments were then performed as described in Section 2. 
Data are expressed as in Fig. IA. C: H-69 and SY5Y cells were treated for 10 min with medium alone (open bars) or forskolin 50 yM (vertical 
bars) and then stimulated for 5 min with 20% FBS. Data are expressed as in Fig. 2. Basal values of pmol of 32P incorporated by MBPlminlmg 
protein are 7.15 f 0.62 and 2.2 f 0.52 for H-69 and SYSY cells, respectively (n = 6). 
activity to a greater extent than DNA synthesis, whose inhibi- 
tion was only partial. This might be due to activation of 
alternative pathways for DNA synthesis after the MAP kinase 
blockage, to a partial desensitization or to metabolic degrada- 
tion of the analogue. since DNA synthesis and MAP kinase 
activity were measured 48 h and 15 min after BIM treatment, 
respectively. 
It is well known that in most of the cell types tested, SST 
receptors are negatively coupled to AC and therefore, they 
decrease intracellular CAMP formation [4]. Although in the 
two cell lines tested BIM is capable of inhibiting forskolin- 
stimulated AC, it is unlikely that this is responsible for inhibi- 
tion of proliferation since CAMP is a growth-suppressant in 
both cell lines. In fact, elevation of intracellular CAMP levels 
either by 8-BrcAMP or forskolin prevented both DNA syn- 
thesis and MAP kinase activation. 
Both H-69 and SYSY cells possess VDCCs on their plas- 
malemma [13,14]. We have previously shown that, in SCLC 
cells, proliferation depends, at least in part, upon the presence 
of extracellular Ca2+ and that in these cells Ca2+ antagonists 
are capable of inhibiting DNA synthesis [21]. Since in excita- 
ble cells SST has been shown to inhibit VDCCs function 
[11,12], and thereby hormone release, we hypothesized that 
BIM could interfere with the release of some autocrine growth 
factor by inhibiting Ca 2’ influx. Moreover, it has been shown 
that in some types of cells, like PC12 cells, MAP kinase ac- 
tivity is stimulated by influx of Ca2+ through VDCCs [17]. 
However, in fura-f loaded cells we could not demonstrate any 
effect of the analogue on depolarization-induced Cazi rise. It 
should be said however, that this technique is not sensitive 
enough to detect small effects, such as a l&20% decrease. 
Growth factors, by activating the Na+/H+ exchange, induce 
an increase in intracellular pH and this cytoplasmic alkalini- 
zation is considered a permissive event for DNA synthesis to 
occur [22]. It has been reported that in enteric endocrine cells 
SST causes an acidification of intracellular pH, dependent on 
extracellular Na+ and inhibited by amiloride [18]. If BIM 
inhibited the Na+/H+ exchange in our cells, this event would 
be a good candidate responsible for the analogue’s antipro- 
liferative action. But we verified that in both cell lines the 
analogue did not have any effect on intracellular pH. 
In conclusion, to our knowledge this is the first evidence 
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that stimulation of SST receptors inhibits MAP kinase activity 
which parallels inhibition of cell proliferation. Our data, 
showing that BIM inhibits MAP kinase activity stimulated 
by both IGF-1 and carbachol, indicate that BIM acts at a 
very early post-receptor level and at some step common to 
the signalling cascade initiated by both tyrosine kinase and G- 
protein coupled receptors leading to MAP kinase activation. 
Having excluded an involvement of CAMP, Ca2+ and pH, a 
tyrosine phosphatase activity, which has recently been found 
to be associated with SST receptors [23,24], might be sug- 
gested as responsible for the analogue’s action. 
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